Skip to main content

Table 2 Antimicrobial activity of omadacycline against Gram-negative bacilli organisms

From: Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Organism/organism group (number of isolates) Number (cumulative %) of isolates at MIC (mg/L) of: MIC50 MIC90 %S %R
≤0.06 0.12 0.25 0.5 1 2 4 8 16 32
Enterobacterales (651) 1 (0.2) 0 (0.2) 11 (1.8) 86 (15.1) 182 (43.0) 151 (66.2) 101 (81.7) 63 (91.4) 31 (96.2) 25 (100.0) 2 8   
  Ceftazidime-non-susceptible (275) 1 (0.4) 0 (0.4) 5 (2.2) 30 (13.1) 64 (36.4) 59 (57.8) 51 (76.4) 31 (87.6) 15 (93.1) 19 (100.0) 2 16   
  Tetracycline-resistant (401)   0 (0.0) 1 (0.2) 40 (10.2) 108 (37.2) 76 (56.1) 66 (72.6) 54 (86.0) 31 (93.8) 25 (100.0) 2 16   
  Tigecycline-non-susceptible (55)       0 (0.0) 2 (3.6) 12 (25.5) 18 (58.2) 23 (100.0) 16 32   
Escherichia coli (260)   0 (0.0) 8 (3.1) 60 (26.2) 107 (67.3) 52 (87.3) 13 (92.3) 8 (95.4) 0 (95.4) 12 (100.0) 1 4   
  Carbapenemase-producing (19)    0 (0.0) 6 (31.6) 6 (63.2) 4 (84.2) 3 (100.0)     1 4   
  ESBL phenotype positive (134) a   0 (0.0) 6 (4.5) 28 (25.4) 57 (67.9) 16 (79.9) 9 (86.6) 6 (91.0) 0 (91.0) 12 (100.0) 1 8   
  ESBL phenotype negative (107) a   0 (0.0) 2 (1.9) 26 (26.2) 44 (67.3) 32 (97.2) 1 (98.1) 2 (100.0)    1 2   
  Tetracycline-resistant (221)   0 (0.0) 1 (0.5) 36 (16.7) 99 (61.5) 52 (85.1) 13 (91.0) 8 (94.6) 0 (94.6) 12 (100.0) 1 4   
  Tigecycline-non-susceptible (1)          0 (0.0) 1 (100.0)     
Klebsiella pneumoniae (271)   0 (0.0) 2 (0.7) 21 (8.5) 54 (28.4) 62 (51.3) 52 (70.5) 44 (86.7) 25 (95.9) 11 (100.0) 2 16 70.5 b,c 13.3 b,c
  Carbapenemase-producing (47)    0 (0.0) 3 (6.4) 0 (6.4) 13 (34.0) 18 (72.3) 6 (85.1) 5 (95.7) 2 (100.0) 4 16 72.3 b,c 14.9 b,c
  ESBL phenotype positive (118) a    0 (0.0) 4 (3.4) 14 (15.3) 25 (36.4) 25 (57.6) 28 (81.4) 13 (92.4) 9 (100.0) 4 16 57.6 b,c 18.6 b,c
  ESBL phenotype negative (106) a   0 (0.0) 2 (1.9) 14 (15.1) 40 (52.8) 24 (75.5) 9 (84.0) 10 (93.4) 7 (100.0)   1 8 84.0 b,c 6.6 b,c
  Tetracycline-resistant (127)    0 (0.0) 2 (1.6) 4 (4.7) 16 (17.3) 31 (41.7) 38 (71.7) 25 (91.3) 11 (100.0) 8 16 41.7 b,c 28.3 b,c
  Tigecycline-non-susceptible (6)         0 (0.0) 2 (33.3) 4 (100.0) 32   0.0 b,c 100.0b,c
Klebsiella aerogenes (30)     0 (0.0) 6 (20.0) 13 (63.3) 4 (76.7) 5 (93.3) 2 (100.0)   2 8   
Enterobacter cloacae (30)     0 (0.0) 3 (10.0) 16 (63.3) 9 (93.3) 0 (93.3) 0 (93.3) 2 (100.0) 2 4 93.3b 6.7 b
  Ceftazidime-non-susceptible (16)     0 (0.0) 1 (6.2) 10 (68.8) 4 (93.8) 0 (93.8) 0 (93.8) 1 (100.0) 2 4 93.8b 6.2 b
  Tetracycline-resistant (11)     0 (0.0) 1 (9.1) 3 (36.4) 5 (81.8) 0 (81.8) 0 (81.8) 2 (100.0) 4 32 81.8b 18.2b
Citrobacter spp. (30) 1 (3.3) 0 (3.3) 1 (6.7) 5 (23.3) 12 (63.3) 5 (80.0) 2 (86.7) 2 (93.3) 2 (100.0)   1 8   
  Tetracycline-resistant (11)    0 (0.0) 2 (18.2) 3 (45.5) 3 (72.7) 1 (81.8) 0 (81.8) 2 (100.0)   2 16   
Serratia marcescens (30)      0 (0.0) 3 (10.0) 21 (80.0) 4 (93.3) 2 (100.0)   4 8   
Acinetobacter baumannii (198) 8 (4.0) 14 (11.1) 15 (18.7) 7 (22.2) 16 (30.3) 38 (49.5) 52 (75.8) 24 (87.9) 18 (97.0) 6 (100.0) 4 16   
Pseudomonas aeruginosa (30)      0 (0.0) 1 (3.3) 0 (3.3) 8 (30.0) 0 (30.0) 21 (100.0) 32 32   
Stenotrophomonas maltophilia (30)     0 (0.0) 4 (13.3) 12 (53.3) 11 (90.0) 3 (100.0)    2 4   
Moraxella catarrhalis (31) 1 (3.2) 25 (83.9) 5 (100.0)         0.12 0.25   
  1. a ESBL: extended-spectrum β-lactamase
  2. b Using FDA identified breakpoints for ABSSSIs
  3. c Using FDA identified breakpoints for CABP